Commentary
Dravet syndrome, formerly known as Severe Myoclonic Epilepsy of Infancy (SMEI), is a devastating neurodevelopmental disorder of intractable epilepsy that begins in early infancy. Tragically, development of affected children is typically on track during the first year of life, whereas progressive developmental decline and prolonged seizures begin to emerge in the second year of life. Individuals with Dravet syndrome are also at higher risk of febrile seizures, prolonged status epilepticus, and of SUDEP (sudden unexplained death in epilepsy) and have a wide range of associated conditions, which all need to be properly treated and managed. Dravet syndrome is now considered a channelopathy with mutations in the gene encoding the α1 subunit (Na v 1.1) of the voltage-gated sodium channel (SCN1A) being one of the most common causes for the condition (1) . A genetic change in SCN1A will present according to its severity, the genetic background of the patient and environmental factors; those factors in turn will determine the clinical presentation of Dravet syndrome. While Dravet syndrome is largely refractory to common antiepileptic drugs, ketogenic diet therapy has recently been used for the management of Dravet syndrome and related severe myoclonic epilepsies (2) , and in one study, 65 percent of patients with Dravet syndrome treated with the ketogenic diet experienced a greater than 50 percent reduction in seizure frequency (3) .
To study pathophysiological mechanisms implicated in Dravet syndrome and develop improved treatment options for the condition, several features of the syndrome have been reproduced by creating mice engineered with a SCN1A gene mutation (mSCN1A) (4) . Animals homozygous for the mutation develop seizures as early as 18 days after birth, and initial mechanistic studies suggested that Nav1.1 plays critical roles in the spike output from parvalbumin-positive interneurons and that altered functions of these inhibitory circuits may contribute to epileptic seizures in the mutant animals (4).
The study by Gu et al. was designed to further characterize mechanisms of circuit excitability in mSCN1A mice and to test possible therapeutic interventions. The authors used hippocampal slice preparations from juvenile mSCN1A mice and employed a combination of extracellular and whole-cell voltage clamp studies with fast voltage-sensitive dye imaging (VSDI). VSDI is a functional imaging technique that uses voltage sensitive dies to study cortical dynamics at high spatial OBJECTIVE: Severe myoclonic epilepsy in infancy (SMEI) or Dravet syndrome is one of the most devastating childhood epilepsies. Children with SMEI have febrile and afebrile seizures (FS and aFS), ataxia, and social and cognitive dysfunctions. SMEI is pharmacologically intractable and can be fatal in 10-20% of patients. It remains to be elucidated how channelopathies that cause SMEI impact synaptic activities in key neural circuits, and there is an ongoing critical need for alternative methods of controlling seizures in SMEI. Using the SCN1A gene knock-in mouse model of SMEI (mSMEI), we studied hippocampal cell and circuit excitability, particularly during hyperthermia, and tested whether an adenosine A1 receptor (A1R) agonist can reliably control hippocampal circuit hyperexcitability. METHODS: Using a combination of electrophysiology (extracellular and whole-cell voltage clamp) and fast voltage-sensitive dye imaging (VSDI), we quantified synaptic excitation and inhibition, spatiotemporal characteristics of neural circuit activity, and hyperthermia-induced febrile seizure-like events (FSLEs) in juvenile mouse hippocampal slices. We used hyperthermia to elicit FSLEs in hippocampal slices, while making use of adenosine A1R agonist N6-cyclopentyladenosine (CPA) to control abnormally widespread neural activity and FSLEs. RESULTS: We discovered a significant excitation/inhibition (E/I) imbalance in mSMEI hippocampi, in which inhibition was decreased and excitation increased. This imbalance was associated with an increased spatial extent of evoked neural circuit activation and a lowered FSLE threshold. We found that a low concentration (50 nM) of CPA blocked FSLEs and reduced the spatial extent of abnormal neural activity spread while preserving basal levels of excitatory synaptic transmission. SIGNIFICANCE: Our study reveals significant hippocampal synapse and circuit dysfunctions in mSMEI and demonstrates that the A1R agonist CPA can reliably control hippocampal hyperexcitability and FSLEs in vitro. These findings may warrant further investigations of purinergic agonists as part of the development of new therapeutic approaches for Dravet syndrome.
Dravet in the Dish: Mechanisms of Hyperexcitability
and temporal resolution (5) . Using extracellular and whole-cell patch-clamp recordings in area CA1, Gu and colleagues first demonstrated increased field excitatory postsynaptic potentials (fEPSPs) and decreased spontaneous inhibitory postsynaptic currents (sIPSCs), indicating an imbalance of excitation and inhibition in this in vitro model of Dravet syndrome. Using VSDI, they further show increased propagation of neural activity in hippocampal circuits from mSCNA1 mice, suggesting that mechanisms that normally limit seizure spread fail to function in this model. Since Dravet syndrome is characterized by a higher incidence of febrile seizures, Gu and colleagues mimicked febrile seizures in the dish by gradually raising the temperature of their preparations in 1 o C/min increments. The authors were able to reliably create febrile seizure-like events (FSLE) as characterized by repetitive seizures evoked by hyperthermia and simultaneously recorded using extracellular and patch-clamp electrodes. Seizures in slices from heterozygous mSCNA1 mice were triggered by temperatures under 39 o C, whereas temperatures >40 o C were needed to trigger seizures in hippocampal slices derived from wild-type animals. Further, seizures in the mutant slices were more than twice as frequent and longer in duration. Together, these data suggest that hippocampal slice preparations from mSCNA1 mice constitute a valid model system of Dravet syndrome that might be a useful tool to screen for effective drug therapies for Dravet syndrome.
The purine ribonucleoside adenosine is a potent regulator of brain activity exerting seizure suppression in all studied models of epilepsy through increased activation of adenosine A 1 receptors (A 1 Rs) (6) . Based on this rationale, Gu and colleagues added the selective A 1 R agonist N6-cyclopentyladenosine to their preparations. As expected, the A 1 R agonist reliably controlled synaptic, circuit, and hyperthermia-induced hyperexcitability in their in vitro Dravet-model system. These effects could be blocked by an A 1 R antagonist confirming the involvement of the A 1 R. Thus, activation of A 1 R signaling might have therapeutic potential for the treatment of seizures in Dravet syndrome.
One limitation of the study from Gu and colleagues is the in vitro approach of therapy assessment. It remains to be determined whether A 1 R stimulation would likewise be effective in suppressing seizures in intact mSCNA1 mice. The in vivo application of CPA might be problematic because systemic A 1 R activation is associated with major cardiovascular and sedative side effects. Furthermore, adenosine-based therapies for the treatment of seizures in Dravet syndrome need to be considered with caution. Patients with Dravet syndrome are at high risk of SUDEP, which in theory may be precipitated by an excess of adenosine in brainstem (7) . Therefore, the therapeutic use of adenosine receptor agonists might not be a safe approach for patients with Dravet syndrome; alternative strategies to harness the therapeutic potential of adenosine might be needed. Therapy with a high-fat low-carbohydrate ketogenic diet might provide such an alternative to harness the therapeutic potential of endogenous adenosine without causing undue side effects (8) . Indeed, clinical studies have shown that ketogenic diet therapy is effective in patients with Dravet syndrome, with limited adverse effects (2, 3) .
To develop more effective treatment options for Dravet syndrome, more research into the underlying mechanisms is needed, and the study from Gu and colleagues provides some interesting insight-in particular in regard to the proneness to febrile seizures, which could nicely be mimicked in the in vitro model. However, it still remains to be determined how hyperthermia triggers seizures in this model system, in particular, and in Dravet syndrome in general.
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